Clinical Trials Logo

Arterial Disease of Legs clinical trials

View clinical trials related to Arterial Disease of Legs.

Filter by:
  • None
  • Page 1

NCT ID: NCT06211127 Recruiting - Clinical trials for Atherosclerosis of Artery

Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, randomized controlled study, which evaluates the effectiveness and safety of cold laser plaque ablation for lower limb arterial stenosis and occlusive lesions from intermittent claudication to chronic threatening limb ischemia.

NCT ID: NCT06182397 Not yet recruiting - Clinical trials for Arterial Disease of Legs

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

MAGICAL BTK
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This is a Pivotal, Prospective, randomised, two arm, placebo controlled, single-blind, multicentre trial that will be conducted at approximately 70 sites; approx. 40 sites with at least 50% of subjects will be recruited from USA and approx. 30 sites OUS - Singapore, Australia and Japan. Each site will be capped at 30 maximum subjects recruited. The main goal of this clinical trial is to determine the effectiveness and safety of the sirolimus drug coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) for the treatment of below the knee arterial disease. Eligible subjects will be randomised in a 1:1 allocation ratio and stratified by recruiting countries. Each subject will be randomized to receive either: 1. MagicTouch PTA sirolimus coated balloon catheter (DCB) in addition to standard balloon angioplasty or 2. Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA).

NCT ID: NCT05054764 Recruiting - Clinical trials for Peripheral Arterial Disease

Promus PREMIER Below The Knee Registry

Start date: August 16, 2021
Phase:
Study type: Observational

The Promus Premier below-the-knee (BTK) drug-eluting stent (DES) is specifically designed to improve BTK vessel patency rates using a platinum-chromium alloy based stent that elutes the anti-restenotic drug everolimus to inhibit neo-intimal hyperplasia. Although DES stents are considered standard of care for certain BTK lesions, there is a paucity of data on the use of DES in the contemporary BTK chronic limb threatening ischemia (CLTI) population, especially in Singapore. The aim of the Promus PREMIER BTK registry is to collect one year data of the Boston Scientific Promus PREMIER BTK DES in BTK lesions in CLTI patients.

NCT ID: NCT04562740 Recruiting - Atherosclerosis Clinical Trials

ABLUMINUS DES BTK Registry - FIM

Start date: August 20, 2020
Phase: N/A
Study type: Interventional

A prospective, single center, single arm non-randomized trial collecting safety and effectiveness data for the ABLUMINUS DES System to treat BTK lesions in subjects with CLI.

NCT ID: NCT04511247 Recruiting - Atherosclerosis Clinical Trials

SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease

FUTURE-BTK
Start date: August 15, 2020
Phase: N/A
Study type: Interventional

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.